Abstract
One of the therapeutics for acute cerebral ischemia is tissue plasminogen activator (t-PA). Using t-PA after 3 hour time window increases the chances of hemorrhage, involving multiple mechanisms. In order to show possible mechanisms of t-PA toxicity and the effect of the free radical scavenger edaravone, we administered vehicle, plasmin, and t-PA into intact rat cortex, and edaravone intravenously. Plasmin and t-PA damaged rat brain with the most prominent injury in t-PA group on 4-HNE, HEL, and 8-OHdG immunostainings. Such brain damage was strongly decreased in t-PA plus edaravone group. For the neurovascular unit immunostainings, occludin and collagen IV expression was decreased in single plasmin or t-PA group, which was recovered in t-PA plus edaravone group. In contrast, matrix metalloproteinase-9 intensity was the strongest in t-PA group, less in plasmin, and was the least prominent in t-PA plus edaravone group. In vitro data showed a strong damage to tight junctions for occludin and claudin 5 in both administration groups, while there were no changes for endothelial (NAGO) and perivascular (GFAP) stainings. Such damage to tight junctions was recovered in t-PA plus edaravone group with similar recovery in Sodium-Fluorescein permeability assay. Administration of t-PA caused oxidative stress damage to lipids, proteins and DNA, and led to disruption of outer parts of neurovascular unit, greater than the effect in plasmin administration. Additive edaravone ameliorated such an oxidative damage by t-PA with protecting outer layers of blood-brain barrier (in vivo) and tight junctions (in vitro).
Keywords: Edaravone, neurovascular unit, oxidative stress, plasmin, tissue plasminogen activator, t-PA, NAGO, GFAP, Acute ischemic stroke, BBB, PBS, Histochemistry, Immunohistochemistry, Immunofluorescence, HEL, BSA, RBEC, Na-F, ANOVA, Brain Cortex, hippocampus, lipid peroxidation, DNA oxidation, ischemia, NO, AQP4, iNOS, 4-HNE, MMP-9
Current Neurovascular Research
Title: Free Radical Scavenger Edaravone Administration Protects against Tissue Plasminogen Activator Induced Oxidative Stress and Blood Brain Barrier Damage
Volume: 7 Issue: 4
Author(s): Violeta Lukic-Panin, Kentaro Deguchi, Toru Yamashita, Jingwei Shang, Xuemei Zhang, FengFeng Tian, Ning Liu, Hiromi Kawai, Tohru Matsuura and Koji Abe
Affiliation:
Keywords: Edaravone, neurovascular unit, oxidative stress, plasmin, tissue plasminogen activator, t-PA, NAGO, GFAP, Acute ischemic stroke, BBB, PBS, Histochemistry, Immunohistochemistry, Immunofluorescence, HEL, BSA, RBEC, Na-F, ANOVA, Brain Cortex, hippocampus, lipid peroxidation, DNA oxidation, ischemia, NO, AQP4, iNOS, 4-HNE, MMP-9
Abstract: One of the therapeutics for acute cerebral ischemia is tissue plasminogen activator (t-PA). Using t-PA after 3 hour time window increases the chances of hemorrhage, involving multiple mechanisms. In order to show possible mechanisms of t-PA toxicity and the effect of the free radical scavenger edaravone, we administered vehicle, plasmin, and t-PA into intact rat cortex, and edaravone intravenously. Plasmin and t-PA damaged rat brain with the most prominent injury in t-PA group on 4-HNE, HEL, and 8-OHdG immunostainings. Such brain damage was strongly decreased in t-PA plus edaravone group. For the neurovascular unit immunostainings, occludin and collagen IV expression was decreased in single plasmin or t-PA group, which was recovered in t-PA plus edaravone group. In contrast, matrix metalloproteinase-9 intensity was the strongest in t-PA group, less in plasmin, and was the least prominent in t-PA plus edaravone group. In vitro data showed a strong damage to tight junctions for occludin and claudin 5 in both administration groups, while there were no changes for endothelial (NAGO) and perivascular (GFAP) stainings. Such damage to tight junctions was recovered in t-PA plus edaravone group with similar recovery in Sodium-Fluorescein permeability assay. Administration of t-PA caused oxidative stress damage to lipids, proteins and DNA, and led to disruption of outer parts of neurovascular unit, greater than the effect in plasmin administration. Additive edaravone ameliorated such an oxidative damage by t-PA with protecting outer layers of blood-brain barrier (in vivo) and tight junctions (in vitro).
Export Options
About this article
Cite this article as:
Lukic-Panin Violeta, Deguchi Kentaro, Yamashita Toru, Shang Jingwei, Zhang Xuemei, Tian FengFeng, Liu Ning, Kawai Hiromi, Matsuura Tohru and Abe Koji, Free Radical Scavenger Edaravone Administration Protects against Tissue Plasminogen Activator Induced Oxidative Stress and Blood Brain Barrier Damage, Current Neurovascular Research 2010; 7 (4) . https://dx.doi.org/10.2174/156720210793180747
DOI https://dx.doi.org/10.2174/156720210793180747 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines
Current Stem Cell Research & Therapy Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry A New Approach of Delivering siRNA to the Cornea and its Application for Inhibiting Herpes Simplex Keratitis
Current Molecular Medicine Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain Barrier Alterations in MDX Mouse, An Animal Model of the Duchenne Muscular Dystrophy
Current Neurovascular Research Protective Effects and Mechanisms of Action of Ulinastatin against Cerebral Ischemia-Reperfusion Injury
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition